Rapid Micro Biosystems (RPID) Cash from Operations Growth (1y) (2021 - 2026)

Rapid Micro Biosystems (RPID) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -7.20%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 132.40%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 1.78%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -35.67%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -84.38%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 185.96%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 122.43%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 16.00%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Rapid Micro Biosystems 90.41 Mn 80.98 Mn 371,000.00 -66.11%

Historic Data

Download Data
DateValue
Mar 31, 2026 -66.11%
Dec 31, 2025 67.24%
Sep 30, 2025 -5.24%
Jun 30, 2025 4.14%
Mar 31, 2025 41.61%
Dec 31, 2024 -4.34%
Sep 30, 2024 11.41%
Jun 30, 2024 -10.11%
Mar 31, 2024 6.96%
Dec 31, 2023 18.52%
Sep 30, 2023 35.73%
Jun 30, 2023 38.68%
Mar 31, 2023 0.68%
Dec 31, 2022 9.56%
Sep 30, 2022 21.77%
Jun 30, 2022 -30.25%
Mar 31, 2022 -49.18%
Dec 31, 2021 -149.22%
Sep 30, 2021 -119.00%